-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Confirms Plans to Accelerate BLA Submission to U.S. FDA for [Fam-] Trastuzumab Deruxtecan
-
Daiichi Sankyo2019-05-28 13:30:01Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in
-
Daiichi Sankyo2019-05-28 13:30:01CLEAR Wisdom Demonstrated First-in-Class, Oral, Once-daily, ACL inhibitor Bempedoic Acid Significantly Lowered
-
Daiichi Sankyo2020-08-03 09:33:40Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral,
-
Daiichi Sankyo2020-08-03 09:34:15Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant
-
Daiichi Sankyo2020-08-03 09:35:00Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions
-
Daiichi Sankyo2020-08-03 09:35:39Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for
-
Daiichi Sankyo2019-05-28 13:30:01Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase
-
Daiichi Sankyo2019-02-05 10:30:35FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for
-
Daiichi Sankyo2019-01-14 12:00:01Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low